HDAC2 and triple-negative breast carcinoma: Future trials should, thus, focus on the role of HDAC-2 in triple negative breast cancer, by explicitly using or, at least, distinguishing triple negative breast cancer samples from other breast cancer subtypes that evidently exhibit distinctive molecular patterns.